eligibility_summary
Eligibility: Adults (>18) with NHIA/study board–confirmed severe asthma, initiating omalizumab, mepolizumab, or benralizumab on/after Jan 1, 2020, and providing informed consent. Exclude: no consent, any biologic use before Jan 1, 2020 or <12‑month washout/prior related trial before index biologic, and comorbid lung disease (e.g., COPD, bronchiectasis, fibrosis) or risk factors (e.g., smoking, harmful exposures) beyond asthma.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Taiwan Severe Asthma Biologic Registry (observational, multi-center) follows adults with severe asthma treated since 2020 with biologic monoclonal antibodies: 1) Omalizumab (anti-IgE mAb): binds free IgE, downregulates FcεRI on mast cells/basophils, dampens allergic cascade. Targets: IgE pathway, mast cells, basophils, B-cell IgE class switching. 2) Mepolizumab (anti-IL-5 mAb): blocks IL-5 signaling, reducing eosinophil maturation/survival. Targets: IL-5 pathway, eosinophils. 3) Benralizumab (anti-IL-5Rα afucosylated mAb): drives NK cell–mediated ADCC, depleting eosinophils/basophils. Targets: IL-5R on eosinophils/basophils. 4) Dupilumab (anti-IL-4Rα mAb): blocks IL-4/IL-13 signaling, suppressing type 2 inflammation. Targets: Th2 axis, B-cell IgE class switching, mucus. 5) Tezepelumab (anti-TSLP mAb): inhibits epithelial alarmin TSLP. Targets: TSLP-TSLPR on dendritic cells, ILC2, Th2.